January 2026
1. DESALEGN D, Fischer S, Bedada Y, Freuer D, et al
   Autoimmunity to mental health: Risk of depression in type 1 diabetes and celiac disease patients - A systematic review, meta-analysis, and bias assessment.
   J Autoimmun. 2026;158:103524.
   

   >> Share

   
   October 2025
2. YEN FS, Wang SI, Hwu CM, Haung CW, et al
   Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes.
   J Autoimmun. 2025;157:103493.
   

   >> Share

   
   August 2025
3. YI X, Zimath PL, Martin-Vazquez E, Oliveira JG, et al
   Transcriptomics of autoimmune diseases identifies FGFR1 as a target for pancreatic beta-cell protection.
   J Autoimmun. 2025;156:103469.
   

   >> Share

   
   July 2025
4. OTT R, Singh T, Schutte-Borkovec K, Scholz M, et al
   Epigenetic differences at immune and type 1 diabetes susceptibility genes in blood from young children after COVID-19 infection.
   J Autoimmun. 2025;156:103468.
   

   >> Share

   
   June 2025
5. LEE YJ, Fang YW, Chen MT, Liou HH, et al
   Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study.
   J Autoimmun. 2025;155:103453.
   

   >> Share

   
   
6. SAKSAGER AB, Hede FD, Barra C
   Autoimmune associated HLAs and T cell autoantigens exhibit common patterns across several autoimmune diseases.
   J Autoimmun. 2025;155:103443.
   

   >> Share

   
   April 2025
7. YANG Y, Liu W, Zhang Z, Zhang Y, et al
   Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agents in autoimmune diseases.
   J Autoimmun. 2025;153:103414.
   

   >> Share

   
   January 2025
8. LI J, Xie Z, Yang L, Guo K, et al
   The impact of gut microbiome on immune and metabolic homeostasis in type 1 diabetes: Clinical insights for prevention and treatment strategies.
   J Autoimmun. 2025;151:103371.
   

   >> Share

   
   
9. AROWOSEGBE A, Guo Z, Vanderleeden E, Derr AG, et al
   Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats.
   J Autoimmun. 2025;151:103358.
   

   >> Share

   
   April 2024
10. DO JS, Arribas-Layton D, Juan J, Garcia I, et al
    The CD318/CD6 axis limits type 1 diabetes islet autoantigen-specific human T cell activation.
    J Autoimmun. 2024;146:103228.
    

    >> Share

    
    March 2024
11. GARCIA-LOZA I, Perna-Barrull D, Aguilera E, Almenara-Fuentes L, et al
    Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes.
    J Autoimmun. 2024;145:103196.
    

    >> Share

    
    October 2023
12. KISHIMOTO TK, Fournier M, Michaud A, Rizzo G, et al
    Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
    J Autoimmun. 2023;140:103125.
    

    >> Share

    
    August 2023
13. POYSTI S, Silojarvi S, Brodnicki TC, Catterall T, et al
    Gut dysbiosis promotes islet-autoimmunity by increasing T-cell attraction in islets via CXCL10 chemokine.
    J Autoimmun. 2023;140:103090.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share